Lakewood-Amedex Biotherapeutics Inc LABT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
-
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
-
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
-
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
-
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
-
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
-
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
-
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Trading Information
- Previous Close Price
- $0.49
- Day Range
- $0.28–0.36
- 52-Week Range
- $0.28–98.20
- Bid/Ask
- $0.26 / $0.26
- Shares Outstanding
- 2.37M
- Market Cap
- $734,603.28
- Volume/Avg
- 40M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://lakewoodamedex.com
Valuation
|
Metric
|
LABT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.16 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LABT
|
|---|---|
Quick Ratio | 7.30 |
Current Ratio | 7.70 |
Interest Coverage | −58.39 |
Quick Ratio
LABT
Profitability
|
Metric
|
LABT
|
|---|---|
Return on Assets (Normalized) | −361.72% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −682.07% |
Return on Assets
LABT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|sdP@Fw | LOCK|Jv?r | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|M$%>mG! | LOCK|KJ@x | $83B | |||
| Moderna Inc
MRNA
| LOCK|$v#%^p | LOCK|L% | $80B | |||
| argenx SE ADR
ARGX
| LOCK|YlvJxdm | LOCK|@# | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?$jv?J^ | LOCK|&r | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$z&><D | LOCK|k?jZ> | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|M^@!&%&# | LOCK|!%<@ | $28B | |||
| Incyte Corp
INCY
| LOCK|>F@J&^% | LOCK|l<g | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|>>pvLD | LOCK|^<Y | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|NQl^#Y | LOCK|%WH | $14B |
United States